Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.
Source: FDA drug label - pyrimethamine
Brand names: Daraprim
Dihydrofolate Reductase Inhibitor Antimalarial · Dihydrofolate Reductase Inhibitors
2 interactions on record
Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.
Source: FDA drug label - pyrimethamine
However, the concomitant use of other antifolic drugs or agents associated with myelosuppression including sulfonamides or trimethoprim-sulfamethoxazole combinations, proguanil, zidovudine, or cytostatic agents (e.g., methotrexate), while the patient is receiving pyrimethamine, may increase the risk of bone marrow suppression.
Source: FDA drug label - pyrimethamine